Immunotherapy in colorectal cancer: current achievements and future perspective.
Immunotherapy in colorectal cancer: current achievements and future perspective.
复制标题
结直肠癌免疫治疗：当前成就和未来展望
DOI：
10.7150/ijbs.64077
复制
发表时间：
2021
影响因子：
9.2
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Fan A;Wang B;Wang X;Nie Y;Fan D;Zhao X;Lu Y
继在许多类型的晚期实体瘤中取得巨大成功之后，对用于治疗结直肠癌（CRC）的免疫疗法的兴趣日益增长。鉴于引人注目的长期持久缓解，两种程序性细胞死亡1（PD-1）阻断抗体，pembrolizumab和nivolumab（联合或不联合伊匹单抗）已被批准用于治疗错配修复缺陷和微卫星不稳定性高（dMMR-MSI-H）的转移性结直肠癌（mCRC）患者。在过去的2年中，多项将免疫治疗纳入MSI-H转移癌和早期的一线治疗的随机对照试验相继报道了实践改变的结果。此外，新的有趣的进展，以扩大免疫治疗的疗效mCRC是错配修复熟练和低微卫星不稳定性（pMMR-MSI-L）证明了潜在的好处，为绝大多数mCRC病例。癌症疫苗和过继性细胞治疗（ACT）的进展也受到了极大的关注。本文就上述研究进展进行综述，并重点介绍目前具有广泛临床应用价值的免疫治疗反应性预测生物标志物。
Following dramatic success in many types of advanced solid tumors, interest in immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given the compelling long-term durable remission, two programmed cell death 1 (PD-1)-blocking antibodies, pembrolizumab and nivolumab (with or without Ipilimumab), have been approved for the treatment of patients with metastatic colorectal cancer (mCRC) that is mismatch-repair-deficient and microsatellite instability-high (dMMR-MSI-H). Practice-changing results of several randomized controlled trials to move immunotherapy into the first-line treatment for MSI-H metastasis cancer and earlier stage were reported successively in the past 2 years. Besides, new intriguing advances to expand the efficacy of immunotherapy to mCRC that is mismatch-repair-proficient and low microsatellite instability (pMMR-MSI-L) demonstrated the potential benefits for the vast majority of mCRC cases. Great attention is also paid to the advances in cancer vaccines and adoptive cell therapy (ACT). In this review, we summarize the above progresses, and also highlight the current predictive biomarkers of responsiveness in immunotherapy with broad clinical utility.
登录
查看更多内容
影响因子：
32.4
作者：
Ebert, Peter J. R.;Cheung, Jeanne;Mellman, Ira
通讯作者：
Mellman, Ira
DOI：
10.1073/pnas.93.25.14827
发表时间：
1996-12-10
影响因子：
11.1
作者：
Carrithers, SL;Barber, MT;Waldman, SA
通讯作者：
Waldman, SA
DOI：
10.1126/science.aar3593
发表时间：
2018-10-12
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Cristescu R;Mogg R;Ayers M;Albright A;Murphy E;Yearley J;Sher X;Liu XQ;Lu H;Nebozhyn M;Zhang C;Lunceford JK;Joe A;Cheng J;Webber AL;Ibrahim N;Plimack ER;Ott PA;Seiwert TY;Ribas A;McClanahan TK;Tomassini JE;Loboda A;Kaufman D
通讯作者：
Kaufman D
影响因子：
30.5
作者：
通讯作者：
--
DOI：
10.1016/b978-0-12-802576-5.00008-5
发表时间：
2017-01-01
期刊：
ANTI-ANGIOGENESIS STRATEGIES IN CANCER THERAPIES
影响因子：
--
作者：
Davis, Paul J.;Mousa, Shaker A.
通讯作者：
Mousa, Shaker A.